demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
breast cancer - adjuvantbreast cancer - HER2-positivebreast cancer - HR positive
breast cancer - adjuvantes-BC - HER2 positive - (neo)adjuvant (NA)la/mBC - HER2 positive - 2nd Line (L2)es-BC - HR positive - (neo)adjuvant (NA)
trastuzumab emtansine EMILIA